RT Journal Article
SR Electronic
T1 Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
JF Diabetes Care
JO Diabetes Care
FD American Diabetes Association
SP 666
OP 670
DO 10.2337/dc13-1473
VO 37
IS 3
A1 Sarkar, Gayatri
A1 Alattar, May
A1 Brown, Rebecca J.
A1 Quon, Michael J.
A1 Harlan, David M.
A1 Rother,  Kristina I.
YR 2014
UL http://care.diabetesjournals.org/content/37/3/666.abstract
AB OBJECTIVE Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes.RESEARCH DESIGN AND METHODS Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period.RESULTS High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction.CONCLUSIONS Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.